COPENHAGEN, Denmark--(BUSINESS WIRE)--Epitherapeutics Aps announced today the receipt of funding from two of the leading Danish life science investor groups, Novo A/S and SEED Capital Denmark to advance the discovery and development of new cancer treatments by leveraging breakthroughs in the field of Epigenetics.
